147 related articles for article (PubMed ID: 37221697)
1. Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype-phenotype translation.
Frederiksen T
Basic Clin Pharmacol Toxicol; 2023 Aug; 133(2):113-123. PubMed ID: 37221697
[TBL] [Abstract][Full Text] [Related]
2. Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole.
Frederiksen T; Areberg J; Raoufinia A; Schmidt E; Stage TB; Brøsen K
Clin Pharmacol Ther; 2023 Feb; 113(2):360-369. PubMed ID: 36350097
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine.
Frederiksen T; Areberg J; Schmidt E; Stage TB; Brøsen K
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):983-993. PubMed ID: 33932135
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
5. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.
Frederiksen T; Areberg J; Schmidt E; Bjerregaard Stage T; Brøsen K
Clin Pharmacol Ther; 2021 Jan; 109(1):150-159. PubMed ID: 32599653
[TBL] [Abstract][Full Text] [Related]
6. Does ethnicity impact CYP2D6 genotype-phenotype relationships?
Frederiksen T; Areberg J; Schmidt E; Stage TB; Brøsen K
Clin Transl Sci; 2023 Jun; 16(6):1012-1020. PubMed ID: 36869607
[TBL] [Abstract][Full Text] [Related]
7. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Caudle KE; Sangkuhl K; Whirl-Carrillo M; Swen JJ; Haidar CE; Klein TE; Gammal RS; Relling MV; Scott SA; Hertz DL; Guchelaar HJ; Gaedigk A
Clin Transl Sci; 2020 Jan; 13(1):116-124. PubMed ID: 31647186
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
9. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
Hicks JK; Swen JJ; Gaedigk A
Curr Drug Metab; 2014 Feb; 15(2):218-32. PubMed ID: 24524666
[TBL] [Abstract][Full Text] [Related]
10. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.
Dalton R; Lee SB; Claw KG; Prasad B; Phillips BR; Shen DD; Wong LH; Fade M; McDonald MG; Dunham MJ; Fowler DM; Rettie AE; Schuetz E; Thornton TA; Nickerson DA; Gaedigk A; Thummel KE; Woodahl EL
Clin Transl Sci; 2020 Jan; 13(1):147-156. PubMed ID: 31536170
[TBL] [Abstract][Full Text] [Related]
11. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.
Hongkaew Y; Gaedigk A; Wilffert B; Ngamsamut N; Kittitharaphan W; Limsila P; Sukasem C
Sci Rep; 2021 Feb; 11(1):4158. PubMed ID: 33603025
[TBL] [Abstract][Full Text] [Related]
12. A Review of the Important Role of
Taylor C; Crosby I; Yip V; Maguire P; Pirmohamed M; Turner RM
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33143137
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
14. Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data.
Frederiksen T; Smith RL; Wollmann BM; Areberg J; Molden E
Clin Pharmacokinet; 2021 Nov; 60(11):1475-1486. PubMed ID: 34121163
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
Elmokadem A; Bruno CD; Housand C; Jordie EB; Chow CR; Lesko LJ; Greenblatt DJ
J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221
[TBL] [Abstract][Full Text] [Related]
16. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
17.
Molden E; Jukić MM
Front Pharmacol; 2021; 12():650750. PubMed ID: 33967790
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
Wu C; Jiang XL; Shen HW; Yu AM
Biochem Pharmacol; 2009 Sep; 78(6):617-24. PubMed ID: 19445902
[TBL] [Abstract][Full Text] [Related]
20. The genomic landscape of
Sivadas A; Rathore S; Sahana S; Jolly B; Bhoyar RC; Jain A; Sharma D; Imran M; Senthilvel V; Divakar MK; Mishra A; Sivasubbu S; Scaria V
Pharmacogenomics; 2024 Feb; 25(3):147-160. PubMed ID: 38426301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
